-
公开(公告)号:US06635627B1
公开(公告)日:2003-10-21
申请号:US09424785
申请日:1999-11-29
申请人: Véronique Stoven , Gérard Lenoir , Jean-Yves Lallemand , Jean-Philippe Annereau , Joël Barthe , Sylvain Blanquet
发明人: Véronique Stoven , Gérard Lenoir , Jean-Yves Lallemand , Jean-Philippe Annereau , Joël Barthe , Sylvain Blanquet
IPC分类号: A61K3166
CPC分类号: A61K31/00 , A61K31/165 , A61K31/198 , A61K31/475 , A61K31/675 , A61K31/704 , A61K45/06 , A61K2300/00
摘要: The invention concerns a novel approach for treating cystic fibrosis using, in particular, anti-cancer chemotherapy. For the treatment of cystic fibrosis it proposes the use of at least one product which when administered to a patient brings about the expression or overexpression of an ABC carrier compound, in particular glutathione carrier. Preferably, the products used are anti-cancer products whose administration brings about the expression of MRP and/or MDR protein. The invention is also applicable to the treatment of rheumatoid polyarthritis or asthma. More specifically, the compounds are selected among cyclophosphamide, aclarubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, zorubicin, pirabucin, colchicine, videsine, vinorelbine, vincristine, binblasine, azithromycin, erythromycin, ifosmamide, N-acetyl cysteine, N-acetyl lysine and/or a CFTR protein fragment comprising the NBF1 domain.
摘要翻译: 本发明涉及使用特别是抗癌化学疗法治疗囊性纤维化的新方法。 对于囊性纤维化的治疗,它提出使用至少一种产品,其在给予患者时引起ABC载体化合物,特别是谷胱甘肽载体的表达或过表达。 优选地,所用的产品是抗癌产品,其给药引起MRP和/或MDR蛋白的表达。 本发明也适用于治疗类风湿关节炎或哮喘。 更具体地说,这些化合物选自环磷酰胺,阿柔比星,多柔比星,柔红霉素,表柔比星,伊达比星,佐立菌素,比拉布丁,秋水仙素,维生素,长春瑞滨,长春新碱,双倍体碱,阿奇霉素,红霉素,异环酰胺,N-乙酰半胱氨酸,N-乙酰基赖氨酸和 /或包含NBF1结构域的CFTR蛋白片段。